Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Deferred Taxes (2022 - 2025)

Core Laboratories (CLB) has 4 years of Deferred Taxes data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Deferred Taxes rose 259.95% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $4.0 million, up 198.84%, while the annual FY2024 figure was -$674000.0, 106.23% down from the prior year.
  • Deferred Taxes reached $1.4 million in Q3 2025 per CLB's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $11.9 million in Q2 2023 and bottomed at -$3.9 million in Q4 2023.
  • Average Deferred Taxes over 4 years is $1.1 million, with a median of $1.3 million recorded in 2025.
  • Peak YoY movement for Deferred Taxes: tumbled 202.03% in 2024, then surged 259.95% in 2025.
  • A 4-year view of Deferred Taxes shows it stood at -$2.2 million in 2022, then crashed by 76.16% to -$3.9 million in 2023, then skyrocketed by 85.5% to -$572000.0 in 2024, then soared by 345.8% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $1.4 million in Q3 2025, $1.3 million in Q2 2025, and $1.8 million in Q1 2025.